Transcript
Dr. Neal Bhatia: And how do we, again, get dermatologists to pay attention to some of these long-term markers? I mean, most wouldn't be following ACR responses. We're probably not doing radiography or getting good X-rays. I mean, is there something else, like correlating skin clearance, that helps? Is there disease remission or a functional assessment in their joints that would help the dermatologist? And where else should we be asking those questions?
Dr. Lourdes Perez-Chada: You mean in a patient who has established psoriatic arthritis?
Dr. Neal Bhatia: Yeah.
Dr. Lourdes Perez-Chada: So, yeah, for sure, you will not be doing an ACR20 assessment in your clinic. There is a nice patient-reported outcome measure that could be used in clinic because it's patient-facing, and that can give you an idea of how the patient is doing, which is the PsAID, the Psoriatic Arthritis Impact of Disease questionnaire. And it has a cutoff of four. So, if I'm not wrong, equal to or under four means that a patient is at an acceptable disease state. Above that number, it means that the patient is not doing well in terms of their psoriatic arthritis. So maybe that's something that's feasible to use in the clinic.
Dr. Neal Bhatia: Which is good. And really, that brings us to the biggest question: What should dermatologists be communicating to rheumatologists? When we are seeing those patients and we're either sharing the management or we're passing the management back and forth, what should we be communicating about to make sure that their target improvement is reached, that we're keeping efficacy high, keeping costs down, and making sure safety signals are not being missed? What should be the role with rheumatologists? Because we've had those discussions with allergists about urticaria and contact dermatitis and our atopics, but with rheumatologists, there seems to be a little bigger gap. What should we be doing a little bit better among dermatologists?
Dr. Lourdes Perez-Chada: So it's funny because that question came up this weekend when I was at the National Psoriasis Foundation Future Leaders meeting. The rheumatologist who was co-chairing this session with me, Alexis Ogdie, was saying that she's not expecting to receive the patient with the films already ordered. What she cares about is the referral of a patient who they believe has a higher risk of having psoriatic arthritis, and that they would be doing the physical assessment and ordering the necessary imaging. If there is a serological marker that could be used, it is CRP. So that's something that the dermatologist can order in advance to better inform that initial visit with a rheumatologist. And then you mentioned something in terms of skin clearance. So, of course, the dermatologist should aim to achieve near-clear skin because that's what we are tasked to do.
But it's not uncommon to observe that a patient who has responded very well from a skin standpoint is not responding as well in the joints and axial disease, if they have that. So you will not always observe that they move in the same direction, and that's what also makes the management complicated because—
Dr. Neal Bhatia: No, completely.
Dr. Lourdes Perez-Chada: So, is that answering your question?
Dr. Neal Bhatia: It totally does. Yeah. Actually, that's very comprehensive. But I'm going to leave you with one last question before we wrap up. If you could change one thing about how dermatologists are approaching psoriatic arthritis today, whether it be approaching treatment, the diagnosis, the monitoring, or the assessments, if there's one thing you could change that would get dermatologists to be more involved in managing psoriatic arthritis, what would you tell them?
Dr. Lourdes Perez-Chada: Screen and refer. I think screening for psoriatic arthritis is the first challenge. If you're not thinking about psoriatic arthritis, then you're not asking about psoriatic arthritis. If you're not asking, you will not find it, and then you will not treat the patient. So I think the first thing that we should be doing is thinking of psoriatic arthritis and screening for it.
Dr. Neal Bhatia: Which makes perfect sense. It goes back to just the way we led off: If we're not looking for it, we're not going to find it. And that's the key. Well, Dr. Perez-Chada, this was really great and very comprehensive. And I think it's a necessary subject for all of our colleagues in dermatology here because, again, this is not something that we necessarily want to lose as part of our practice. And we want to share the decisions with the rheumatologist rather than compete with them, if you will. We also want the patients to have their best outcomes and not have to rotate therapies to find their sweet spot. So this is really informative, and thank you so much for sharing this time with us.
Dr. Lourdes Perez-Chada: Thank you. Thank you for inviting me.
Dr. Neal Bhatia: Very good. And this was another installment of Dermatology Dialogues, and we'll catch you on the next one.

